[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482149":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":60,"collaborators":42,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":42,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":42,"enrollmentInfo":71,"targetDuration":42,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":42,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Table Salt, then Salt Substitute","EXPERIMENTAL","The two intervention periods will last 16 days with a 19-day washout period in between.\n\nDuring the first 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table.\n\nParticipants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing.\n\nIn addition, participants will undergo standard of care hemodialysis (typically 3x\u002Fweek) and have their blood chemistries measured according to the usual standard of care during the study.",[13,14],"Dietary Supplement: Standard Table Salt","Dietary Supplement: Salt Substitute",{"label":16,"type":10,"description":17,"interventionNames":18},"Salt Substitute, then Standard Table Salt","The two intervention periods will last 16 days with a 19-day washout period in between.\n\nDuring the first 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table.\n\nParticipants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing.\n\nIn addition, participants will undergo standard of care hemodialysis (typically 3x\u002Fweek) and have their blood chemistries measured according to the usual standard of care during the study.",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Standard Table Salt","Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.",[16,9],[26],"Morton Standard Table Salt",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Salt Substitute","Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.\n\nSalt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.",[16,9],[32],"Morton Lite Salt",[34],{"name":35,"affiliation":36,"role":37},"David Charytan, MD MSc","NYU Langone Medical Center","PRINCIPAL_INVESTIGATOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","617-935-1572",null,"David.charytan@Nyulangone.org",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Zoe Rimler","631-357-1333","Zoe.Rimler@nyulangone.org",[49],{"facility":5,"status":42,"city":50,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":42},"New York","10016","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-74.00597,40.71427,{"lat":58,"lon":57},{"type":61,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100482149","potassium-containing-salt-substitute-in-hemodialysis-dependent-end-stage-kidney-disease-100482149",false,"NCT05558267","Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease","A Randomized, Pilot, Double-Blind Crossover Trial of a Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease","Inclusion Criteria:\n\n1. Receiving outpatient maintenance HD therapy.\n2. Age ≥ 21 years.\n3. Negative serum pregnancy test for women of child-bearing capacity. Childbearing capacity will be defined by report of menstruation within ≤ 6 months.\n\nExclusion Criteria:\n\n1. Currently incarcerated.\n2. Insufficient capacity for informed consent.\n3. Non-hemolyzed serum potassium concentration \\>6.0 mEq\u002FL within ≤30 days.\n4. Unscheduled HD for hyperkalemia within ≤30 days.\n5. Attendance at ≤10 of last 13 scheduled OP HD sessions.\n6. Co-habiting family member with known hyperkalemia.\n7. Co-habiting family with ≥stage 3b chronic kidney disease or chronic kidney disease of unknown severity.\n8. Hemoglobin \\\u003C 8.0 mg\u002FdL.\n9. Use of other potassium supplements.","ALL","21 Years",{"count":72,"type":73},20,"ESTIMATED","INTERVENTIONAL",[76],"NA","16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.",[79],"End Stage Kidney Disease",[81],"Potassium-Containing Salt Substitute","NOT_YET_RECRUITING","2026-03-10",{"date":85,"type":86},"2026-03-12","ACTUAL",{"date":88,"type":73},"2027-01-15",{"date":90,"type":73},"2027-06-15",{"name":5,"class":6},1]